710 Palm Dr. Liverpool TX. 77577
Mb.tbld@protonmail.com
Office number: 1-713-515-3903

TBLD Development Corporation

EXECUTIVE SUMMARY

TBLD Development Corporation is a medical business development company, partnered with Vyripharm Biopharmaceuticals, where we hold worldwide patents to the blockchain extraction process of all botanicals, more specifically Cannabinoidiol (CBD). Our patent includes integrated systems and methods of evaluating *cannabis* and cannabinoid products for public safety, quality control and quality assurance, research and public use. Unlike existing extraction processes, our process, in finite detail, evaluates the integrity of CBD oil from seed to human consumption and beyond. All key farmer/growers worldwide will be required to have a license for extraction. We hold technology, position and full proprietary access to farmers/growers with requirements to monitor the growing process in detail. We determine the designated strain the specified grower. The blockchain extraction process precedes our proprietary nanotechnology delivery system utilized in conjunction with all existing medical imaging platforms, i.e. PET/CT, SPECT, and MRI. Our imaging process allows us to view (in real-time) the affected area of the body while simultaneously delivering the CBD oil to the targeted area where we evaluate the strand/strain efficacy and potency. Lastly, we formulate and personalized, precision-based treatment regimens for ongoing maintenance, preventive care, and nutraceuticals (for ALL ailments) that encompasses DNA matching in human and animal subjects. Lastly, we formulate personalized, precision-based treatment regimens, at the cellular level, for ongoing maintenance, preventive care, and nutraceuticals (for ALL ailments) that encompass DNA matching in human and animal subjects. All other CBD based products in the world have no public safety evaluation methods, nor personalized, precision-based treatment standards in place. The current extraction methods are at risk for chemical and toxic contamination, furthermore, will have inevitable, negative short- and long-term effects on human and animal subjects.

PROBLEM

Retail and medically based CBD products have entered the market with no botanical extraction evaluation, quality control and assurance methods in place, rendering the public at risk with no accountability measures. Issues currently at hand,

- Public & Medical CBD products contain chemicals and toxins
- Product consistency
- Integrity of Potency
- Short- and Long-Term effects of toxicity at a cellular level
- Lack of knowledge of what and how to treat

Our patented extraction process evaluates the integrity of all CBD oil and determines the specific strain and strand at output, thus creating a worldwide standard for personalized, precision-based treatment and nutraceutical supplements, etc.

710 Palm Dr. Liverpool TX. 77577
Mb.tbld@protonmail.com
Office number: 1-713-515-3903

TBLD Development Corporation

Solution

We provide an accountability system, through our patented technology that evaluates the extraction of all CBD oil worldwide. This ensures that customers in the medical and retail space receive guaranteed, certified pure and the most optimal CBD oil and products available. Medical patients and retail customers can now rest assured the have a chemical & toxin free CBD product that is optimal for their own personal treatment regimen for epilepsy, cancer, CTE, PTSD, etc.

Opportunity

Cannabis (CBD Oil) industry sales have reached $10.8 Billion dollars, a growth of 30% over the previous year and a 400% over the last 4 years. By 2023, the market has estimated that Cannabis (CBD Oil) will comprise $50 Billion dollars annually. This is prior to full legalization of cannabis nationwide. Once full legalization has been established the market is slated to spike to 200% from its current state overnight. The current overall cannabis market is flooded with interest in multifaceted uses.

- 80% of the cannabis market is geared towards medical usage.
- 23,000+ scientific papers released on medical cannabis and its application
- Chronic Pain ($77 Billion Market), medical cannabis positioned to replace existing therapy • Pharmaceutical Sleep Drugs topping $102 Billion, presents yet another opportunity
- Crohn's Disease ($7.6 Billion Market) 90% improvements with CBD in Israel
- FDA Approved epilepsy drug (Epidiolex) already moved to Schedule 5, down from Schedule 1

Our patented process is positioned to capture ALL existing extraction business to ensure quality control and assurance measures are in place for use in the medical and recreational space. Furthermore, the components in place through our patent (proprietary imaging technology) provides precision-based usage in the overall medical space for treatment at the cellular level. This is similar to stem cell, yet at a much more affordable price point for the public. The public has already shown an inevitable desire for CBD, we now personalize it to their need and ongoing maintenance requirements.

In summary, ALL farmer/growers who wish to provide CBD to the medical space or who care to produce optimal botanical (CBD) oils to the world will have to licensed do so. Also, all precision-based, personalized treatment regimens will require our proprietary imaging kit (which includes our nanotechnology) and CBD provided from our licensed providers.

TBLD Development Corporation

710 Palm Dr. Liverpool TX. 77577
Mb.tbld@protonmail.com
Office number: 1-713-515-3903

COMPETITIVE ADVANTAGES

Our business competitive advantages over the competitors is multifaceted:

- All research and development, as well as, technology and product testing have been implemented at MD Anderson, UTMB, Baylor College of Medicine, and The University of Houston (currently the first Center of Excellence – ensuring QC/QA of final extracted oil product)

- Our R&D arm of the technology is run by Dr. Elias Jackson, Director of Science and Dr. Jerry Bryant, CTO - Chief Technology Officer (both of which have developed the technology and patents)

- The FDA & DEA have both requested our assistance in bringing QA/QC to the medical & recreational cannabis market.

- Patent is secured both nationally and internationally: All farmer/growers, worldwide, must be licensed to extract any botanical, specifically CBD, if production is slated for the medical space.

- Quality Control and Assurance: All farmers/growers have a public safety standard to ensure safe production of CBD oil for medical and recreational use, unlike the current market positioned as a free for all with no accountability.

BUSINESS MODEL

Current Revenue Sources

- Farmer / Grower Licensing
- Proprietary Imaging Adjudication & Medical Institution Licensing
- Professional Athlete Personalize Treatment (At Completion Test/Treatment Platform)

Farmer / Grower Licensing

All farmer / growers will be licensed directly from TBLD to produce CBD. Licensing will range from $5MM to $35MM (approximate cost) per farmer/grower. This cost point is slated to yield a 60%+ margin per license. We are focusing on the top 200 farmer/growers nationwide to start production. With an average licensing fee of $10MM, our immediate revenue is slated to be $2 Billion in grower relationships alone.

710 Palm Dr. Liverpool TX. 77577
Mb.tbld@protonmail.com
Office number: 1-713-515-3903

TBLD Development Corporation

Imaging & Medical Institution Licensing

Due to the imaging CPT code (can be billed through insurance), our proprietary imaging kits are already accepted on major insurance platforms. The kits house patented nanotechnology utilized in the imaging evaluation process. The net revenue from each imaging kit engaged will be approximately $1200. Each patient can be scanned up to 4x's per year ($4800/patient/year) to confirm treatment results. They will also have to be imaged to engage in further personalized, precision-based CBD oil therapy. There are 38 million patients on 2 medications or more, 90%. The immediate adoption of our targeted CBD therapy will be a seamless due to the already accepted insurance protocol. A 1% market change will be 380,000 patients, getting the initial scan will render $456MM in revenue.

Professional Athlete Treatment

Each athlete will have their very own SAFE personalized, precision-based treatment regimen upon completing their initial evaluation. We will know the strain and strand that will provide their most optimal recovery time and healing time. The treatment kits provided to each athlete will range from $4000 - $8000/month, depending on the treatment regimen needed. The NFL, alone, has an estimated 1900+ active players who require recovery therapy and wish to prolong their careers. The ongoing treatment revenue here is $21MM+ per year for the NFL players alone.

TEAM

- ***Martin Banda, Jr, President*** **–** Martin 26 years of construction development and planning in the commercial and residential space. His experience has also fostered key relationships in the medical and technology space.

experience in commercial financial business, business assessment, and management.

710 Palm Dr. Liverpool TX. 77577
Mb.tbld@protonmail.com
Office number: 1-713-515-3903

TBLD Development Corporation

FINANCIALS

Costs

Year 1 - NFL Clinical Data Trial Platform $30,000,000.00

Annual

Variable: Planning & Development $12,000,000.00
Fixed: Salaries and Operations $ 7,000,000.00
$49,000,000.00



Revenue

Initial Grower Licensing (YR1 - 50 Farmer/Growers @ $10MM) $500,000,000.00
Professional Athlete Treatment Regimen (1500 players) $ 75,000,000.00
Imaging Kits implementation (500 Medical Practices) $360,000,000.00
$935,000,000.00



TBLD Development Corporation

710 Palm Dr. Liverpool TX. 77577
Mb.tbld@protonmail.com
Office number: 1-713-515-3903

Our breakeven point will occur at our 5-month mark with implementing acquisition at 4 farmers/growers monthly. Positive cashflow will occur thereafter at 6 months of operation. The overall profit potential, Year 1, $886,000,000.00. We look to incur a 40% increase in grower licensing per quarter due to the variety of strands and strains needed. The professional athletic network will draw an 30% increase in new athlete treatment adoption due to them wanting to have an edge and faster recovery time. The imaging kits will experience a spike truly at 300% adoption over the next few months after launching in the community medical sector.

Funding Required

The business is currently seeking $1Bn in initial funding. The initial $250MM 2019 Q1 funding will be used to finance the development of the licensing infrastructure and the clinical trial test/treat platform immediately. We will also deploy the IP legal team regarding patent infringement and moving forward in place of licensing acquisition. We will also immediately, secure financial sources to help our farmer/grower relationships regarding financing their licensing fees. At the injection of the $250MM 2019 Q2 funding, the company will focus on partnership / development and will start revenue at the implementation of licensing and will drive the adoption of imaging kits in the medical institutions. The clinical data test/treat trial will also foster the immediate revenue of personal treatment regimens for the professional athletes. The 2019 Q3 funding of $250MM will implement the data platform and the assimilation of the business and research world strategy. The tailored treatment regimens will be available in real-time and can be implemented once the specific strain/strand combination is ready for use (ready 60 days after initial seeding). The $250MM 2019 Q4 funding, will position us in establishing the infrastructure throughout the entire world and activate the compound distribution channel due to the implementation of the imaging ancillary service licensing.

Exit Strategy

After Full Completion of $1Bn Injection:
10 year Amortized @ 10% I/O payment: $25MM+, Quarterly w/ no early payoff penalty after 5 years.